{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:49:41Z","timestamp":1791082181245,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ejmech.2025.117729","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T21:14:09Z","timestamp":1746738849000},"page":"117729","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["First-in-class dual inhibitors of MASTL and Aurora A kinase: Discovery of selective cyclohexa[b]thiophenes with potent anticancer activity"],"prefix":"10.1016","volume":"293","author":[{"given":"Somaya A.","family":"Abdel-Rahman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossam","family":"Nada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9074-3331","authenticated-orcid":false,"given":"Moustafa T.","family":"Gabr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117729_bib1","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/carcin\/bgm019","article-title":"A census of mitotic cancer genes: new insights into tumor cell biology and cancer therapy","volume":"28","author":"P\u00e9rez de Castro","year":"2007","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ejmech.2025.117729_bib2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11912-016-0524-y","article-title":"Cell cycle regulation and melanoma","volume":"18","author":"Xu","year":"2016","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.ejmech.2025.117729_bib3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12876-018-0786-y","article-title":"Mitotic and apoptotic activity in colorectal neoplasia","volume":"18","author":"Kohoutova","year":"2018","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.ejmech.2025.117729_bib4","doi-asserted-by":"crossref","first-page":"6322","DOI":"10.1002\/cam4.3141","article-title":"MASTL: a novel therapeutic target for cancer malignancy","volume":"9","author":"Fatima","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.ejmech.2025.117729_bib5","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3389\/fcell.2018.00162","article-title":"The oncogenic functions of MASTL kinase","volume":"6","author":"Marzec","year":"2018","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2025.117729_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/cells9071624","article-title":"Kinase-independent functions of MASTL in cancer: a new perspective on MASTL targeting","volume":"9","author":"Conway","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2025.117729_bib7","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1016\/j.apsb.2023.03.013","article-title":"Emerging roles of Aurora-A kinase in cancer therapy resistance","volume":"13","author":"Zheng","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2025.117729_bib8","first-page":"295","article-title":"Aurora-A kinase as a promising therapeutic target in cancer","volume":"5","author":"D'Assoro","year":"2015","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2025.117729_bib9","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.tips.2017.05.003","article-title":"Aurora A kinase is a priority pharmaceutical target for the treatment of cancers","volume":"28","author":"Damodaran","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2025.117729_bib10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/978-3-642-19065-0_11","article-title":"ARPP-19 and protein phosphatase 2A: shifting the mitosis paradigm","volume":"53","author":"Haccard","year":"2011","journal-title":"Results Probl. Cell Differ."},{"key":"10.1016\/j.ejmech.2025.117729_bib11","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.222364","article-title":"Greatwall kinase at a glance","volume":"131","author":"Castro","year":"2018","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.ejmech.2025.117729_bib12","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1038\/s41388-018-0295-z","article-title":"MASTL overexpression promotes chromosome instability and metastasis in breast cancer","volume":"37","author":"Rogers","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.117729_bib13","first-page":"7283","article-title":"Mastl overexpression is associated with epithelial to mesenchymal transition and predicts a poor clinical outcome in gastric cancer","volume":"14","author":"Sun","year":"2017","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ejmech.2025.117729_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.104459","article-title":"MASTL is enriched in cancerous and pluripotent stem cells and influences OCT1\/OCT4 levels","volume":"25","author":"N\u00e4rv\u00e4","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.ejmech.2025.117729_bib15","first-page":"2413","article-title":"MASTL is a potential poor prognostic indicator in ER+ breast cancer","volume":"21","author":"Zhuge","year":"2017","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2025.117729_bib16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12943-018-0848-3","article-title":"MASTL induces Colon cancer progression and chemoresistance by promoting Wnt\/\u03b2-catenin signaling","volume":"17","author":"Uppada","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2025.117729_bib17","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1186\/s12964-024-01783-8","article-title":"Activity-based protein profiling and global proteome analysis reveal MASTL as a potential therapeutic target in gastric cancer","volume":"22","author":"Choi","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.ejmech.2025.117729_bib18","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.biopha.2017.05.118","article-title":"E2F8 confers cisplatin resistance to ER+ breast cancer cells via transcriptionally activating MASTL","volume":"92","author":"Tian","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2025.117729_bib19","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1038\/s41388-021-01681-0","article-title":"Mass-spectrometry-based proteomic correlates of grade and stage reveal pathways and kinases associated with aggressive human cancers","volume":"40","author":"Monsivais","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.117729_bib20","doi-asserted-by":"crossref","first-page":"71182","DOI":"10.18632\/oncotarget.11511","article-title":"A first generation inhibitor of human greatwall kinase, enabled by structural and functional characterisation of a minimal kinase domain construct","volume":"7","author":"Ocasio","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2025.117729_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/ph14070647","article-title":"Discovery and characterization of a novel MASTL inhibitor MKI-2 targeting MASTL-PP2A in breast cancer cells and oocytes","volume":"14","author":"Kang","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2025.117729_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.571601","article-title":"MKI-1, a novel small-molecule inhibitor of MASTL, exerts antitumor and radiosensitizer activities through PP2A activation in breast cancer","volume":"10","author":"Kim","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2025.117729_bib23","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1021\/acsmedchemlett.4c00177","article-title":"Novel 2,7-naphthyridine compounds as MASTL inhibitors for treating cancer","volume":"15","author":"Sabnis","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.117729_bib24","doi-asserted-by":"crossref","first-page":"19234","DOI":"10.1021\/acs.jmedchem.4c01659","article-title":"Discovery of highly selective inhibitors of microtubule-associated serine\/threonine kinase-like (MASTL)","volume":"67","author":"Gallego","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117729_bib25","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.86976","article-title":"The ATM-E6AP-MASTL axis mediates DNA damage checkpoint recovery","volume":"12","author":"Li","year":"2023","journal-title":"Elife"},{"key":"10.1016\/j.ejmech.2025.117729_bib26","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1042\/BST20130066","article-title":"The structural mechanisms that underpin mitotic kinase activation","volume":"41","author":"Dodson","year":"2013","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.ejmech.2025.117729_bib27","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/med.21399","article-title":"Aurora-A kinase: a potent oncogene and target for cancer therapy","volume":"36","author":"Yan","year":"2016","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2025.117729_bib28","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s12276-021-00635-6","article-title":"Aurora kinase A, a synthetic lethal target for precision cancer medicine","volume":"53","author":"Mou","year":"2021","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ejmech.2025.117729_bib29","first-page":"1377","article-title":"Aurora kinase A inhibitors: promising agents in antitumoral therapy","volume":"18","author":"Malumbres","year":"2014","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejmech.2025.117729_bib30","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/med.20203","article-title":"Biology of Aurora A kinase: implications in cancer manifestation and therapy","volume":"31","author":"Karthigeyan","year":"2011","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2025.117729_bib31","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1038\/onc.2016.292","article-title":"Aurora A kinase activates YAP signaling in triple-negative breast cancer","volume":"36","author":"Chang","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.117729_bib32","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1038\/s41388-022-02293-y","article-title":"Aurora kinase A inhibition induces synthetic lethality in SMAD4-deficient colorectal cancer cells via spindle assembly checkpoint activation","volume":"41","author":"Shi","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.117729_bib33","doi-asserted-by":"crossref","first-page":"32","DOI":"10.4132\/jptm.2016.10.17","article-title":"Aurora kinase A is a prognostic marker in colorectal adenocarcinoma","volume":"51","author":"Koh","year":"2017","journal-title":"J. Pathol. Transl. Med."},{"key":"10.1016\/j.ejmech.2025.117729_bib34","doi-asserted-by":"crossref","first-page":"7522","DOI":"10.1038\/s41598-018-24982-z","article-title":"Aurora kinase A (AURKA) interaction with wnt and Ras-MAPK signalling pathways in colorectal cancer","volume":"8","author":"Jacobsen","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.117729_bib35","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.3389\/fonc.2020.01354","article-title":"Targeting aurora A kinase (AAK) in platinum-resistant high grade serous ovarian cancer","volume":"10","author":"Ganapathi","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2025.117729_bib36","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1159\/000439194","article-title":"Role of Aurora-A in ovarian cancer: a meta-analysis","volume":"38","author":"He","year":"2015","journal-title":"Oncol. Res. Treat."},{"key":"10.1016\/j.ejmech.2025.117729_bib37","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00412-003-0265-1","article-title":"Regulation of Aurora-A kinase on the mitotic spindle","volume":"112","author":"Kufer","year":"2003","journal-title":"Chromosoma"},{"key":"10.1016\/j.ejmech.2025.117729_bib38","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.tcb.2005.03.004","article-title":"Aurora kinases, aneuploidy and cancer, a coincidence or a real link?","volume":"15","author":"Giet","year":"2005","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.ejmech.2025.117729_bib39","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1083\/jcb.201105058","article-title":"Aurora A and Aurora B jointly coordinate chromosome segregation and anaphase microtubule dynamics","volume":"195","author":"H\u00e9garat","year":"2011","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.117729_bib40","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13065-022-00852-8","article-title":"Design, synthesis, anticancer evaluation and docking studies of novel 2-(1-isonicotinoyl-3-phenyl-1H-pyrazol-4-yl)-3-phenylthiazolidin-4-one derivatives as Aurora-A kinase inhibitors","volume":"16","author":"Beniwal","year":"2022","journal-title":"BMC Chem"},{"key":"10.1016\/j.ejmech.2025.117729_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106901","article-title":"A novel class of pyrazole analogues as aurora kinase A inhibitor: design, synthesis, and anticancer evaluation","volume":"141","author":"Yevale","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.117729_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115740","article-title":"Design and synthesis of coenzyme A analogues as Aurora kinase A inhibitors: an exploration of the roles of the pyrophosphate and pantetheine moieties","volume":"28","author":"Bellany","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117729_bib43","doi-asserted-by":"crossref","first-page":"6831","DOI":"10.1002\/chem.201900815","article-title":"Construction of a shape-diverse fragment set: design, synthesis and screen against Aurora-A kinase","volume":"25","author":"Zhang","year":"2019","journal-title":"Chemistry"},{"key":"10.1016\/j.ejmech.2025.117729_bib44","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/cbdd.13850","article-title":"Design strategies, SAR, and mechanistic insight of Aurora kinase inhibitors in cancer","volume":"98","author":"Sankhe","year":"2021","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2025.117729_bib45","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.2217\/fon.15.154","article-title":"The role of alisertib in treatment of peripheral T-cell lymphomas","volume":"11","author":"Gallop-Evans","year":"2015","journal-title":"Future Oncol."},{"key":"10.1016\/j.ejmech.2025.117729_bib46","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1021\/pr300819m","article-title":"Cancer cell resistance to aurora kinase inhibitors: identification of novel targets for cancer therapy","volume":"12","author":"Hrabakova","year":"2013","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.ejmech.2025.117729_bib47","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3389\/fonc.2015.00278","article-title":"Aurora kinase inhibitors: current status and outlook","volume":"5","author":"Bavetsias","year":"2015","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2025.117729_bib48","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ebiom.2017.10.026","article-title":"Solid cancer treatment with Aurora kinase inhibitors: towards a personalized medicine","volume":"25","author":"Ulisse","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejmech.2025.117729_bib49","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1021\/acsptsci.0c00096","article-title":"Cyclohepta[b]thiophenes as potential antiproliferative agents: design, synthesis, in vitro, in vivo anticancer evaluation","volume":"3","author":"Abdel-Rahman","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.ejmech.2025.117729_bib50","article-title":"Thiophene derivative-loaded nanoparticles mediate anticancer activity through the inhibition of kinases and microtubule assembly","volume":"4","author":"Abdel-Rahman","year":"2021","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ejmech.2025.117729_bib51","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1021\/jm00261a002","article-title":"2,4-Diaminothieno(2,3-d)pyrimidines as antifolates and antimalarials. 1. synthesis of 2,4-diamino-5,6,7,8-tetrahydrothianaphthena(2,3-d)pyrimidines and related compounds","volume":"16","author":"Rosowsky","year":"1973","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117729_bib52","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202000069","article-title":"Novel 2-cyanoacrylamido-4,5,6,7-tetrahydrobenzo[b]thiophene derivatives as potent anticancer agents","volume":"353","author":"Sroor","year":"2020","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.ejmech.2025.117729_bib53","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1158\/1535-7163.MCT-10-0106","article-title":"Analysis of FDA-approved anti-cancer agents in the NCI60 panel of human tumor cell lines","volume":"9","author":"Holbeck","year":"2010","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.117729_bib54","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s00432-024-06003-x","article-title":"3D cultivation of non-small-cell lung cancer cell lines using four different methods","volume":"150","author":"Malmros","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.117729_bib55","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1039\/D3RA08086B","article-title":"Lithocholic acid derivatives as potent modulators of the nuclear receptor ROR\u03b3t","volume":"14","author":"Abdel-Rahman","year":"2024","journal-title":"RSC Adv."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425004945?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425004945?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T08:16:35Z","timestamp":1748420195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425004945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":55,"alternative-id":["S0223523425004945"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117729","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-in-class dual inhibitors of MASTL and Aurora A kinase: Discovery of selective cyclohexa[b]thiophenes with potent anticancer activity","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117729","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117729"}}